1	Outcome of SARS-CoV-2 infection linked to MAIT cell activation and cytotoxicity:
2	evidence for an IL-18 dependent mechanism
3	Authors:
4	H. Flament ^{1,•} , M. Rouland ^{2,•} , L. Beaudoin ^{2,•} , A. Toubal ^{2,†} , L. Bertrand ^{2,†} , S. Lebourgeois ^{3,†} , Z.
5	Gouda ² , C. Rousseau ² , P. Soulard ² , M. Hurtado-Nedelec ¹ , S. Luce ² , K. Bailly ² , M. Andrieu ² , C.
6	Boitard ^{2,4} , A. Vallet-Pichard ^{2,5} , JF. Gautier ⁶ , N. Ajzenberg ⁷ , B. Terrier ⁸ , F. Pene ^{2,9} , J. Ghosn ¹⁰ , Y.
7	Yazdanpanah ¹⁰ , B. Visseaux ³ , D. Descamps ³ , JF. Timsit ¹¹ , R.C. Monteiro ¹ , A. Lehuen ^{2,*}
8	Author affiliations:
9	1. Immunological Dysfunction Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude
10	Bernard University Hospital, Paris, France; University of Paris, Center for Research on
11	Inflammation (CRI), Inserm U1149 & CNRS ERL8252, Inflamex Laboratory, Paris, France.
12	2. University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, Université de Paris,
13	Paris, France.
14	3. Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard
15	University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR
16	1137, University of Paris, Paris, France.
17	4. Department of Diabetology, Assistance Publique-Hôpitaux de Paris, Cochin University
18	Hospital, Paris, France.
19	5. Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Cochin University

- 20 Hospital, Paris, France.
- 6. Department of Diabetes and Endocrinology, Lariboisière Hospital, AP-HP, Paris, France. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 21

22	7. Department of Hematology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard
23	University Hospital, Paris, France; University of Paris, LVTS, INSERM 1148, Paris, France.
24	8. Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris Cochin University
25	Hospital, Paris, France.
26	9. Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin University
27	Hospital, Paris, France.
28	10. Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris,
29	Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling
30	Evolution (IAME) UMR 1137, University of Paris, Paris, France.
31	11. Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de
32	Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials
33	Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
34	
35	Corresponding Author: Agnès Lehuen, Institut Cochin, Université de Paris, CNRS UMR 8104
36	and INSERM U1016, 123 Boulevard de Port-Royal, 75014 Paris, France. ORCID: 0000-0002-
37	0450-3321; Phone: +331 76 53 55 90; E-mail: agnes.lehuen@inserm.fr.
38	•,†: These authors contributed equally to this work.
39	
40	Keywords: MAIT cells, COVID-19, SARS-CoV-2, inflammation, innate immune cells.
41	

43 Abstract:

Immune system dysfunction is paramount in Coronavirus disease 2019 (COVID-19) severity 44 and fatality rate. Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells involved in 45 mucosal immunity and protection against viral infections. Here, we studied the immune cell 46 landscape, with emphasis on MAIT cells, in a cohort of 182 patients including patients at 47 various stages of disease activity. A profound decrease of MAIT cell counts in blood of critically 48 ill patients was observed. These cells showed a strongly activated and cytotoxic phenotype 49 that positively correlated with circulating pro-inflammatory cytokines, notably IL-18. MAIT cell 50 alterations markedly correlated with disease severity and patient mortality. SARS-CoV-2-51 infected macrophages activated MAIT cells in a cytokine-dependent manner involving an 52 53 IFN α -dependent early phase and an IL-18-induced later phase. Therefore, altered MAIT cell 54 phenotypes represent valuable biomarkers of disease severity and their therapeutic manipulation might prevent the inflammatory phase involved in COVID-19 aggravation. 55

- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64

65 Introduction:

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the etiologic agent 66 responsible for the recent outbreak of Coronavirus disease 2019 (Covid-19) that started in 67 December 2019. Cellular targets of the SARS-CoV-2 are primarily upper- and lower respiratory 68 tract cells as well as pulmonary cells^{1,2}. The SARS-CoV-2 infection results in a wide range of 69 clinical signs, from asymptomatic to life-threatening Acute Respiratory Distress Syndrome 70 (ARDS), caused by a deleterious anti-viral immune response in the lung³⁻⁵. In serious cases, 71 the overbalanced local immune response damages the airways and may lead to 72 noncardiogenic pulmonary edema, hypoxia, and need for artificial ventilation and/or 73 oxygenation^{6,7}. 74

75 Innate-like T cells including Mucosal-associated invariant T (MAIT), invariant Natural Killer T (iNKT), and γδT cells, are known to be key actors of pulmonary mucosal immunity, of mucosal 76 tissue repair and are involved in the immune response to numerous respiratory pathogens^{8–} 77 78 ¹³. Innate Lymphoid cells (ILCs) have also emerged as important mediators in tissue protection and repair during lung viral infection^{14,15}. Among them, MAIT cells recognize bacterial 79 metabolites derived from the riboflavin synthesis pathway and presented by the major 80 histocompatibility complex (MHC) class-I-related protein (MR1)^{16,17}. It has been established 81 that MAIT cells are activated during viral infections, especially in blood and lungs^{18–20}. MAIT 82 cell activation by viruses is TCR-independent and cytokine-dependent^{18,20}. During both acute 83 and chronic viral infections, MAIT cell blood frequency is reduced while expression of HLA-DR, 84 PD-1, CD38 and CD69 is upregulated^{18–20,22–24}. Upon acute viral infection, they produce high 85 levels of granzyme B (GzB)²⁰. 86

87 In COVID-19 patients, alteration of peripheral lymphocyte and myeloid subsets is associated with clinical characteristics and treatment efficiency^{25–27}. However, status of MAIT cells, 88 remain unknown in COVID-19 patients. Here, we analyzed blood MAIT cells of COVID-19 89 patients with different disease severity status from Infectious Disease Unit (IDU) (n=51) and 90 Intensive Care Unit (ICU) (n=51). These patients were compared with uninfected controls 91 92 (n=80) matched for age, sex and comorbidities. In COVID-19 patients, blood MAIT cells are altered in relation with disease severity and mortality. Macrophages infected in vitro with 93 94 SARS-CoV-2 stimulate MAIT cells. Our study supports MAIT cells as a new indicator of COVID-19 gravity and suggest them as target to reduce COVID-19 morbidity. 95

96

97 Results:

98 Adaptive and innate T cell frequency in the blood of COVID-19 patients.

We first began our study of immune cells in SARS-CoV-2 infection by analyzing the frequency 99 100 and phenotype of lymphocytes in blood samples from COVID-19 patients as well as (agematched BMI-matched) non-infected donors (Fig. 1a). Fifty-one COVID-19 patients had been 101 admitted in IDU (moderate cases) and 51 patients in ICU (severe cases) (with a death rate of 102 103 41% in ICU). As controls, we included 80 healthy non-infected donors as well as donors with 104 various pathologies (diabetes, obesity) to match those affecting hospitalized COVID-19 patients (Fig. 1a). All characteristics and health data of recruited patients and controls are 105 106 listed in Table 1. Whole blood was collected and stained for flow cytometry to analyze the frequencies of both innate and adaptive T lymphocytes following the gating strategy explained 107 108 in **Supplementary Figure 1**. A majority of patients with COVID-19 presented a significant 109 reduction of T cells in IDU, more pronounced in ICU patients (Fig. 1b), confirming earlier 110 reports^{28,29}. Among CD3⁺ T cells, there was a slight increase of blood $\alpha\beta$ T cells frequency in 111 ICU patients, mirrored by a decrease of $\gamma\delta T$ cells (Fig. 1c). Both CD4⁺ and CD8⁺ T cell frequency among CD3⁺ T cells were not significantly impacted by SARS-CoV-2 infection whereas T 112 regulatory cell frequency was significantly reduced in both IDU and ICU patients compared to 113 uninfected controls (Fig. 1d). We observed a collapse of $V\alpha 7.2^+$ CD161⁺ MAIT cell frequency 114 115 among CD3⁺ cells in COVID-19 patients, down to a tenth of those observed in uninfected controls (Fig. 1e). We confirmed that MAIT cell markers CD161 and Va7.2 allowed similar MAIT 116 117 cell identification as with MR1 tetramers loaded with the active ligand 5-(2oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) in all three groups of patients 118 (Supplementary Fig. 2). Among MAIT cells, the CD8⁺ subset was further reduced in COVID-19 119 120 patients, but to a lesser extent in ICU compared to IDU (Fig. 1f). We therefore observed a 121 dramatic decrease of blood MAIT cells in COVID-19 patients, with an alteration of MAIT cell subsets repartition. 122

123

124 MAIT cells are activated and cytotoxic in COVID-19 patients.

125 As MAIT cell frequency is extremely reduced in blood of COVID-19 patients, we analyzed both their surface markers expression as well as their cytokine production. An activated phenotype 126 with a dramatic increase of CD69 expression was observed in COVID-19 patients, with a 127 128 median of 41% CD69⁺ MAIT cells in IDU and 67% in ICU patients, with some reaching 100% 129 (Fig. 2a). Blood MAIT cells also displayed a significant increase of the NK cell-associated activation CD56⁺ marker compared to controls, that was highest in ICU patients (Fig. 2a). 130 Accordingly, double positive CD56⁺ CD69⁺ MAIT cell frequency was increased in IDU patients 131 and even more in ICU patients (Fig. 2a). The frequency of MAIT cells co-expressing CCR6, the 132

receptor for the CCL20 chemokine (a tissue-migrating marker) and survival CD127 marker was
 decreased, suggesting that the low circulating MAIT cell frequency might reflect their
 migration into inflamed infected tissues and/or activation-induced cell death (Supplementary
 Fig. 3a). MAIT cell activation in some patients might be associated with secondary infections
 and presence of bacteria in the blood (Supplementary Fig. 3b).

In contrast to MAIT cells, CD69⁺ expression on CD8⁺ T cell remained moderate (median of 10%)
in both IDU and ICU although increased compared to uninfected controls (Supplementary Fig.
3c). Frequency of CD56⁺ CD8⁺ T cells was similar in all three groups of patients. Consequently,
the frequency of effector CD56⁺ CD69⁺ CD8⁺ T cells was modestly increased in COVID-19
patients compared to uninfected controls (Supplementary Fig. 3c).

143 We next investigated with unsupervised methods the phenotype of MAIT cells, on 9 flowcytometry parameters. We first compared MAIT cells of COVID-19 patients to uninfected 144 145 controls by Multidimensional scaling (MDS) plots, which revealed a severity progression from 146 non-infected controls to IDU and ICU patients (Fig. 2b). We next performed graphical dimensional reduction by both t-distributed Stochastic Neighbor Embedding (t-SNE) and 147 Uniform Manifold Approximation and Projection (UMAP) that also returned a progressive 148 distribution of MAIT cells from controls to IDU and ICU patients (Fig. 2c and Supplementary 149 Fig. 4a,b). Of note, both CD69 and CD56 markers were critical molecules in the differential 150 151 distribution (Fig. 2d and Supplementary Fig. 4c).

MAIT cell function was then assessed after PMA/ionomycin stimulation by analyzing IFNγ and GzB production in all three groups of patients and IL-2, IL-4, IL-10, IL-17 and TNF in IDU and ICU patients (**Fig. 2e,f** and **Supplementary Fig. 5a**). Production of IFNγ was decreased in COVID-19 IDU patients compared to non-infected controls. However, IFNγ and IL-2 increased 156 in ICU patients compared to IDU patients (Fig. 2e and Supplementary Fig. 5a). In contrast, GzB production progressively increased in stimulated MAIT cells in IDU and ICU patients as 157 compared to controls. Elevated GzB production was also detected in unstimulated MAIT cells 158 from infected patients (Fig. 2f,g and Supplementary Fig. 5b). Such enhanced cytokine and GzB 159 production in ICU patients were not observed in conventional $\alpha\beta T$ cells, $\gamma\delta T$ cells and CD3⁻ 160 161 cells (including NK cells) (Supplementary Fig. 5a,b). Altogether, these results show that blood MAIT cells from COVID-19 patients display an activated/effector phenotype and cytotoxic 162 163 function associated with disease severity.

164

165 Links between MAIT cell activation and other innate immune cell alterations

Following MAIT cell analyses, we further investigated other innate-like immune cell frequency, phenotype and activation in the blood of SARS-CoV-2 infected patients. A significant NK cell, ILC2 and ILC3 frequency reduction in IDU and ICU patients was observed, which was more pronounced for NK cells and ILC2 in COVID-19 patients from ICU (**Fig. 3a**). CD69 expression was higher in all infected patients on NK cells, ILC3, and $\gamma\delta T$ cells whereas it was reduced on ILC2 (**Fig. 3b**).

We sought to identify correlations between MAIT cells and other innate cells in COVID-19 patients. A multiparametric matrix correlation plot showed strong positive correlations between the frequencies of activated MAIT cells (both CD56⁺ and/or CD69⁺ MAIT cells) with CD69⁺ ILC3, NK and γδT cells frequencies as well as CD69⁺ CD56⁺ γδT cells (**Fig. 3c,d**). Several negative correlations were also observed between activation of these populations and their frequencies. CD69 expression on MAIT cells was negatively correlated with ILC3, ILC2 and NK cell frequencies (**Fig. 3c**). Moreover, cytokine production by MAIT cells was also negatively

correlated with ILC3 frequencies and to a lesser extent with ILC2 and NK cell frequencies. Taken together, these data suggest that inflammatory processes in SARS-CoV-2-infected patients involve concomitant activation of MAIT cells with other innate-immune cells associated with loss of these populations' frequencies in blood.

183

184 Fatal SARS-CoV-2 infection is linked with activation and function of MAIT cells.

185 To investigate the impact of immune cell populations on disease outcome, blood samples 186 were analyzed by comparing two groups, surviving versus fatal outcome of COVID-19 infected patients. CD69 expression significantly increased on MAIT, CD8 T, γδT, and NK cells in fatal 187 COVID-19 patients compared to surviving IDU and/or ICU patients (Fig. 4a). MAIT cells 188 displayed the highest activation level in all patients, particularly those with fatal outcomes. 189 We next examined immune cell function relative to disease outcome by measuring 190 191 intracellular cytokines and GzB in stimulated and unstimulated immune cells (Fig. 4b, 192 **Supplementary Fig. 6a,b** and data not shown). IFNy, TNF, and GzB in stimulated MAIT cells 193 and GzB in unstimulated MAIT cells were significantly enhanced in deceased compared to 194 surviving patients with SARS-CoV-2 infection (Fig. 4b and Supplementary Fig. 6a,b). IL-10 production by stimulated $\gamma\delta T$ cells in patients who succumbed was greater compared to 195 surviving COVID-19 patients (Fig. 4b and Supplementary Fig. 6a). Thus, MAIT cell function was 196 197 more associated to mortality than functions of other T cell populations. No modification of IL-2, IL-4, and IL-17 production in CD4⁺, CD8⁺, CD3⁻, $\gamma\delta$ T, and MAIT cells was observed in fatal 198 cases (Fig. 4b and Supplementary Fig. 6a). Moreover, statistical regression analyses identified 199 four MAIT cell markers (IFNy production, stimulated GzB production, unstimulated GzB 200 production, CD69) that defined predictive models for COVID-19 outcome, as tested on a 201

receiver-operating-characteristic (ROC) curve (**Fig. 4c**). In order to have a more global view of individual patients, we generated an heatmap based on multiple immune cell and blood parameters from single uninfected, infected and fatal COVID-19 patients. This analysis highlights activation signatures of non-surviving patients compared to surviving COVID-19 patients and controls (**Fig. 4d**).

207

208 Increased pro-inflammatory cytokine levels correlate with blood MAIT cell alterations.

209 We next analyzed plasma levels of several cytokines by Cytometric Bead Array (CBA) and MSD 210 Quickplex in both surviving IDU and ICU patients as well as non-surviving patients (Fig. 5a,b). IL-6, IL-8, IL-10, IL-15, and IL-18 levels were significantly increased in the plasma of non-211 surviving patients compared to surviving patients, confirming a state of widespread, 212 pronounced inflammation in severe COVID-19 cases ²⁸ (Fig. 5a,b). IFNα2 levels were 213 214 significantly decreased in ICU compared to IDU, although no significant difference between 215 surviving ICU and deceased patients was detected (**Fig. 5b**). IL-1β levels were similar between all three groups (Fig. 5b). Multiparametric matrix correlation plot showed strong positive 216 217 correlation of IL-6, IL-8, IL-10, IL-15, IL-18 levels with frequencies of CD69⁺, and CD69⁺ CD56⁺ MAIT cells in the blood of all COVID-19 patients (**Supplementary Fig. 7a,b**). IFNα2 blood level 218 correlated positively with the production of IFNy, TNF, and IL-2 by MAIT cells (Supplementary 219 220 Fig. 7a).

Separated matrix correlation plot between surviving and non-surviving ICU patients showed different relationships between blood cytokines and GzB production by MAIT cells. In surviving patients, there was a strong negative correlation between blood IL-15 level and spontaneous GzB production by MAIT cells whereas in non-surviving patients there was a strong positive

225 correlation between blood IL-18 level and GzB MAIT production. The link between IL-18 and 226 MAIT cell activation is further supported by high IL-18Ra expression on all blood MAIT cells in control and COVID-19 infected compared to other immune populations (Supplementary Fig. 227 8a,b,c). Interestingly, in non-surviving ICU patients, blood IL-18 level was negatively correlated 228 with IFNα2 blood levels (Fig. 5c). Accordingly, IL-18 blood level was increased in long-term 229 230 infected ICU patients whereas IFN α 2 blood level was decreased in long-term in these patients (Fig. 5d). Of note, CD69⁺ MAIT cell frequency increased as well with time and was highest one 231 232 month after symptoms onset, when death rate was highest among ICU patients. Our data therefore reveal that pro-inflammatory cytokines and IL-10 levels are associated with MAIT 233 cell activation and highlights a unique relationship between plasma IL-18 levels and circulating 234 cytotoxic MAIT cells in fatal cases. 235

236

MAIT cell phenotype and functions are associated with SARS-CoV-2 severity and clinical
 parameters.

As previously reported in our cohort, COVID-19 severity was associated with extended pulmonary damage as evaluated on chest computed tomography (CT) (score from 1:mild to 5:critical) (**Fig. 6a**). PaO₂/FiO₂ ratio was significantly reduced and C-reactive protein (CRP) levels were significantly increased in ICU patients. Both parameters were even more impacted in fatal cases (**Fig. 6b,c**).

A correlation matrix of MAIT cells activation, function and clinical parameters was established for all COVID-19 patients (**Fig. 6d**). It included age, body mass index (BMI), CRP, Simplified Acute Physiology Score II (SAPSII) (an estimator of patient mortality risk at ICU admission), PaO₂/FiO₂ ratio, polymorphonuclear neutrophil (PMN), disease duration and pulmonary

lesions. Analysis of these clinical indicators in light of MAIT cells revealed that on vital parameters, PaO2/FiO2 strongly negatively correlated with CD69⁺ expression, IFNγ and TNF production by MAIT cells, whereas SAPSII score positively correlated with CD69⁺ MAIT cell frequency (**Fig. 6d,e**). Concerning inflammatory markers, CRP level correlated with MAIT cell activation phenotype and cytokine secretion (IL-2, IFNγ and TNF) while PMN frequency positively correlated with CD69⁺ MAIT cell frequency (**Fig. 6d,e**).

254 Principal Component Analysis (PCA) of all COVID-19 patients showed an unsupervised overview of all clinical data, cytokine levels, immune cell frequencies, activation, and functions 255 for each COVID-19 patient (Fig. 6f). The PCA showed the segregation of deceased patients 256 compared to surviving patients with CD69⁺ MAIT cells being the most contributing variable 257 (Fig. 6g and Supplementary Fig. 9). Of note, several parameters also contributed to the 258 259 surviving/fatal cases discrimination vector such as blood IL-8, IL-15, IL-18, CRP, PMN, activated 260 ILC3 and NK cells that we previously found to be correlated to MAIT cell activation (Fig. 3c,d, Supplementary Fig. 9, and Fig. 6d,e). Therefore, altered activation markers and cytokine 261 262 production by blood MAIT cells correlate with clinical parameters and are associated with both severity and disease outcome. 263

264

265 SARS-CoV-2-infected macrophages activate MAIT cell in vitro.

MAIT cells exert antiviral properties that are promoted especially by macrophages ^{18,20}. It has been established that macrophages and monocytes functions are impacted by SAR-CoV-2 infection^{26,27}. Using an *in vitro* co culture model we analyzed whether SARS-CoV-2-infected macrophages impacted MAIT cell phenotype. Blood monocytes isolated from healthy donors were cultured during 7 days and differentiated into mature macrophages (GM-MΦ). GM-MΦ

271 were then infected with SARS-CoV-2 at different multiplicity of infection (MOI) (0.3 or 3) during 2 hours and then cocultured with autologous PBMC or enriched MAIT cells for 24 to 96 272 hours (Fig. 7a). Infected macrophages of 4 healthy donors (MOI=0.3 or 3) induced increased 273 expression of CD69 on MAIT cells, when compared to uninfected macrophages (mock), in a 274 dose dependent manner (Fig. 7b). Of note, although macrophage infection by SARS-CoV-2 was 275 276 similar in all donors (Fig. 7c), level of MAIT cell activation by infected macrophages varied, suggesting intrinsic differences between individuals that modulate MAIT cell response upon 277 infection. Other innate immune cells (yoT and NK cells) were also activated by infected 278 macrophages, however, to a lesser extent than MAIT cells. CD8, CD4 T cells or ILC3 co-culture 279 (MOI=3) were almost unaffected (Fig. 7d). Analysis of several donors showed that MAIT cells 280 were always activated, whereas it was not the case for other innate immune cells (Fig. 7e). 281

282 Since MAIT cells exert their antiviral activity in a cytokine dependent manner^{18,20}, we next 283 analyzed cytokine production by infected macrophages. Gene expression analysis showed that a short-term infection of macrophages by SARS-CoV-2 (24 hours) induced upregulation 284 285 of their Ifnα, Ifnβ, II-1β and II-6 expression compared to uninfected controls whereas II-10, II-15 and *II-18* expression was downregulated. While *Ifnα*, *Ifn*, *II-16*, *II-6*, *II-10* and *II-15* 286 287 expression return to basal levels 4 days after infection, the expression of *II-18* was upregulated (Fig. 7f). Finally, we observed that blockade of type I IFN, IL-12 and IL-18 completely inhibited 288 MAIT cell activation of the donor 4 whereas it was only blocked by type I IFN inhibitor for the 289 donor 5 (Fig. 7g). Altogether this data suggests that MAIT cell activation upon infection by 290 SARS-CoV-2 is a two-step process. Early infection may induce MAIT cell activation through type 291 292 I IFN pathways and later through the IL-18 pathway.

293

294 Discussion:

Our study reveals major MAIT cells alteration in numerous COVID-19 cases. MAIT cell 295 frequency is strongly reduced in greater proportion than all other major T cell subsets and 296 297 they are highly activated with secretion of critical pro-inflammatory cytokines, such as IFNy. MAIT cells possess a strong cytotoxic capability with an increased expression of GzB. 298 Moreover, all these MAIT cell alterations scale with the severity of SARS-CoV-2 infection, from 299 300 mild to fatal cases, and correlate with both plasmatic pro-inflammatory cytokine levels and other innate cell activation. In vitro experiments identified a SARS-CoV-2 macrophage cytokine 301 shift and their ability to stimulate MAIT cells. 302

The frequency of blood MAIT cells was extremely reduced, down to a tenth compared to 303 controls in severe cases of COVID-19³⁰. Several hypotheses might explain this loss of blood 304 MAIT cells. The tissue migration chemokine receptor CCR6 expression is decreased on blood 305 306 MAIT cells during SARS-CoV-2 infection whereas its ligand, CCL20, is expressed by pro-307 inflammatory pulmonary macrophages ³¹. Collapse of MAIT cell frequency in blood may be due to migration of CCR6⁺ MAIT cells in the infected lung where they might participate to local 308 309 immune response, as already demonstrated in other pulmonary infections mediated both by bacteria or viruses ^{18,19}. In addition, a recent study in a limited number of COVID-19 patients 310 showed an increased pulmonary MAIT cell frequency in the broncho-alveolar lavage fluid ³⁰. 311 Low blood MAIT cell frequency may also be due to their apoptosis. Expression of CD127, 312 receptor for the pro-survival cytokine IL-7, is reduced on blood MAIT cells from infected 313 patients. Moreover, MAIT cells are terminal effector T cell with high GzB expression, 314 suggesting limited lifespan³². 315

316 MAIT cell frequency and activation alterations are characteristic of several deleterious inflammatory pathologies, especially metabolic pathologies such as T2D, liver disease or 317 obesity^{10,33–36}. MAIT cell frequency is reduced in blood from patients with those pathologies 318 and they present an exhausted phenotype that may impair their antibacterial response^{34–36}. 319 320 This is of importance as metabolic pathologies are important factors increasing risk of developing severe COVID-19³⁷⁻⁴⁰. Thus, in our study, we matched our controls for 321 comorbidities affecting COVID-19 patients, mainly obesity and diabetes. More than half of the 322 ICU patients of our cohort developed secondary infections from mild tissue-specific infections 323 to life-threatening sceptic shocks. Previous studies showed that high frequency of MAIT cells 324 is associated with survival during sceptic shocks⁴¹. Similarly, patients co-infected by 325 Mycobacterium tuberculosis and HIV are more vulnerable to tuberculosis because of a 326 reduced MAIT cell frequency in blood^{23,42}. COVID-19 patients with metabolic syndromes may 327 therefore be extremely vulnerable to complications because of a diminished ability to fight 328 both primary viral infection and secondary bacterial infections to a persistent depletion of 329 blood MAIT cells. 330

Our data highlights strong positive correlations between blood NK, ILC3, γδT and MAIT cell
 activation. In other lung pathologies such as asthma, CD69⁺-activated NK, ILCs, and MAIT cells
 are associated with airflow limitation⁴³. We observed a significant correlation between MAIT
 cells activation and ILC2 frequency and it is already established that ILC2 are important drivers
 of allergen-induced airway hyperresponsiveness (AHR) after influenza A virus (IAV) infection
 ¹⁴.

Blood cytokine analysis showed increased amounts of type I interferons and pro-inflammatory
cytokines such as IL-6, IL-8 and the immunosuppressive IL-10 cytokines in COVID-19 patients

as previously reported²⁸. Presence of elevated levels of IL-1 β , IL-6, IL-8, and IL-10 are indicative 339 340 of cytokine storms that are major potential complications in severe COVID-19 patients. Moreover, IL-15 and IL-18 levels were increased in COVID-19 patients in relation with disease 341 severity and IL-18 strongly correlated with MAIT cell activation in patients with fatal outcome. 342 In these patients, IFN α 2 level inversely correlated with increased IL-18. During the early 343 344 phases of infection *in vitro*, macrophages produced important amounts of type I interferons which collapsed in later stages, around 4 days post-infection. This is in agreement with the 345 346 ability of SARS-CoV-2 to suppress type I interferon production through numerous structural and non-structural viral proteins⁴⁴ and as highlighted in COVID-19 patient plasma analysis of 347 ICU patients. However, long-term in vitro infected macrophages produce increased levels of 348 349 IL-18 that can activate MAIT cells in COVID-19 corroborating the extremely high blood IL-18 level correlating with MAIT cell activation in deceased patients. Both IL-15 and IL-18 are the 350 most effective pro-inflammatory cytokines capable to activate MAIT cells in a TCR-351 independently manner during viral infection¹⁹. CD56⁺ MAIT cells, which are increased in severe 352 353 cases from our COVID-19 cohort, are known to have a higher capacity to respond to type I IFN and IL-18 cytokines that are key players in MR1-independent MAIT cell responses during viral 354 infection⁴⁵. 355

MAIT cells in inflammatory pathologies are double-edged swords. They can be protective by participating in and supporting pathogen clearance, immune activation and tissue reparation^{10,12,46}. Patients infected with pandemic IAV harbor an inverse correlation between MAIT cell frequencies and disease severity, suggesting a protective role for MAIT cells^{18,20}. Conversely, MAIT cells may fuel detrimental inflammation. Our data suggests a negative role for MAIT cells in severe COVID-19 infection in which their activation and GzB production are the highest. Against infection with Dengue virus (DV), there is a temporal and quantitative

363	association between the activation of MAIT cells and the onset of severe disease ²⁰ . It is
364	interesting to note that both the DV and the SARS-CoV-2 are able to infect macrophages,
365	which then can activate MAIT cells ⁴⁷ . Activation of MAIT cells by infected macrophages
366	through IL-18 may switch MAIT cells toward a detrimental role in these infections.
367	In conclusion, human MAIT cells are activated, displaying a cytotoxic profile in the blood of
368	SARS-CoV-2 infected patients, which is associated with other innate immune cell activation,
369	and a pro-inflammatory environment. Together, these data extend the knowledge of the
370	immune actors involved during SARS-CoV-2 infection. These findings reveal MAIT cells as a
371	valuable biomarker of disease progression and a new target for interventional therapeutic
372	approaches in severe SARS-CoV-2 infection.

All rights reserved. No reuse allowed without permission.

374 Materials and methods:

375 Clinical study design and ethical statement:

One-hundred and two COVID-19 patients admitted in Bichat or Cochin hospitals, Paris, France, 376 between March 23, 2020 and May 29, 2020 were included in this clinical study. For 377 comparisons, blood from 80 uninfected controls of the Quid-Nash project (n=30), 378 Etablissement Français du Sang (EFS) (n= 12), and volunteer donors (n=38) were mostly 379 380 collected before pandemic onset (54/80). Clinical characteristics of the 182 patients are 381 summarized in Fig. 1a and further detailed in Supplementary Table 1. No statistical methods 382 were used to predetermine cohort size. The percentage of lung involvement was evaluated on chest CT with a score of 1 to 5 to represent mild to critical pulmonary lesions damages. 383 384 Simplified Acute Physiology Score (SAPS II) was used to estimate the probability of survival after Intensive Care Unit (ICU) admission. The Ethics Committees approved clinical 385 386 investigations. Informed consent was obtained from each enrolled patient. Patient's from 387 Bichat Hospital (Paris, France) were included in the French COVID cohort (NCT04262921). Ethics approval for this cohort was given on February 5th, 2020 by the French Ethics 388 Committee CPP-Ile de France- VI (ID CRB: 2020-A00256-33). This cohort is sponsored by 389 390 Inserm and supported by the REACTing consortium and by the French Ministry of Health (PHRC n°20-0424). Samples from these patients were derived from samples collected in routine care. 391 Patients from Cochin Hospital (Paris, France) were recruited in the setting of the local 392 RADIPEM biological samples collection derived from samples collected in routine care. 393 Biological collection and informed consent were approved by the Direction de la Recherche 394 Clinique et Innovation (DRCI) and the French Ministry of Research (N°2019-3677). 395 396 Investigations with control patients from QUID-NASH were approved by Comité de Protection

des Personnes de Sud Méditerranée (V) #18.021, N° of QUID project registration: 2018A00311-54.

399

400 Whole blood, PBMC and plasma isolation:

Whole blood samples were collected in EDTA or heparin-coated tubes (Vacutaine, BD Biosciences) from healthy, non-infected, donors; and COVID-19 patients admitted to Cochin, Bichat, or Lariboisière Hospitals in Paris, France. Tubes were centrifugated at 1260*g* for 10 minutes and plasma was collected and frozen at -80°C. PBMCs were isolated by Ficoll-Paque (Lymphosep, Biosera), frozen in 1mL of freezing medium constituted of 90% FCS and 10% DMSO and stored in liquid nitrogen.

407

408 Cytokine measurements:

IL-6, IL-8 and IL-10 were measured in plasma using Human Cytometric Bead Array (CBA) 409 410 Inflammatory Cytokine Kit (BD Biosciences) according to manufacturer's instructions. 411 Acquisitions were performed on a BD FACSLyric cytometer (BD Biosciences) and raw data 412 analyzed with FCAP Array software V3.0 (BD Biosciences). For the IFN α 2 quantification, plasma 413 samples were analyzed with the MSD Quickplex using the Ultra-sensitive assay S-PLEX Human IFN-α2a (reference K151P3S-1) from Meso Scale Diagnostic MSD (Rockville, US) using 25 μL of 414 each sample. Each plasma sample was assayed twice with the average value taken as the final 415 416 result. The unit for Human IFN- α 2a measured in the present study is fg.mL⁻¹.

For IL-18, IL-15 and IL-1β quantification, the plasma samples were analyzed with the MSD
Quickplex using the U-plex Biomarker group 1 (human) Assay (K-15067L-1) from Meso Scale

Diagnostic MSD, using 25 μ L of each (1/2 diluted) sample. Each plasma sample was assayed twice with the average value taken as the final result. The unit for Human IL18, II-15 and IL-1 β measured in the present study is pg.mL⁻¹.

422

423 Flow cytometry:

424 Surface and intracytoplasmic staining were performed on blood samples or PBMC with the

425 following antibodies: CD3 (OKT3), CD19 (HIB19), CD4 (OKT4), CD8 (SK1), Vα7.2 (3C10), TCR-

426 γδ (B1) , CD161 (HP-3G10), CCR6 (G034E3), CD56 (HCD56), CD69 (FN50), CD127 (R34.34),

427 CD218a (H44), IFNγ (4S.B3), TNF (Mab11), , IL-2 (MQ1-17H12), IL-4 (8D4-8), IL-10 (JES3-

428 19F1), IL-17 (BL168), granzyme B (GB11). Full list is described in **Supplementary Table 1**.

429 According to the amount of blood obtained from each patient, surface staining was always

430 performed, and depending on number of cells, intracytoplasmic staining of cytokines and

431 granzyme B were analyzed after stimulation with PMA-ionomycin-brefeldin A. Biotinylated

432 human MR1 tetramers loaded with the active ligand 5-(2-oxopropylideneamino)-6-D-

433 ribitylaminouracil (5-OP-RU) were used to confirm MAIT cells identification. MR1 tetramers

434 were coupled to streptavidin-PE (National Institutes of Health tetramer core facility, USA).

For surface staining, staining of 200μL of blood sample was performed in PBS containing 1%
BSA and 0.05% sodium azide. After surface staining, cells were fixated using BD FACS Lysing
Solution (BD Biosciences, #349202) according to the manufacturer's instructions. Data
acquisition was performed using a BD Biosciences LSR Fortessa. Flow cytometric analyses were
performed with the FlowJo analysis software V10.6.2 (Tree Star).

For intracellular labelling, thawed PBMCs were treated with DNAse (0.05 mg.mL⁻¹) (#D4263,
Sigma-Aldrich, USA) in RPMI (#61870-010, Gibco, USA) and incubated at 37°C, 5% CO₂ during

442 30 minutes. Depending on the number of PBMCs obtained from each patient, intracytoplasmic 443 staining of cytokines and granzyme B were analyzed with stimulation with PMA (#P-8139, Sigma-Aldrich, USA), ionomycin (#I-0634, Sigma-Aldrich, USA) and Brefeldin A (#B-7651, 444 Sigma-Aldrich, USA) and/or only Brefeldin A. Stimulated cells were incubated during 6h at 37 445 °C in RPMI medium supplemented with 10% FCS, 1% HEPES, 1% Penicillin/Streptomycin and 446 447 stimulated with PMA (25 ng.mL⁻¹) and ionomycin (1 μ g.mL⁻¹), in the presence of brefeldin A (10 µg.mL⁻¹). After surface staining, cells were fixed and permeabilized with a 448 Cytofix/Cytoperm kit (#554714, BD Biosciences, USA), then were washed using Perm/Wash 449 buffer (BD Biosciences, #554723) and incubated at 4 °C in the dark for 30 min with antibodies 450 against cytokines and GzB (listed above). 451

452

453 In vitro culture:

454 For virus culture, the Vero E6 kidney epithelial cells line was acquired from the American Type 455 Culture Collection (#CRL-1586, ATCC, USA) (LGC standards SARL, Illkirch, France). Vero E6 cells 456 were cultured in DMEM (GibcoTM) supplemented with 10% of heat-inactivated fetal bovine 457 serum (FBS, GibcoTM) (Thermo Fisher Scientific, Waltham, MA, 209 USA) and maintained at 37°C in a humidified atmosphere containing 5% CO₂. The viral strain of human SARS-CoV-2 458 was obtained from a nasopharyngeal positive PCR sample. SARS-CoV-2 primo-culture stock 459 460 used in this study was produced in Vero E6 cells and titrated by lysis plaque assay ⁴⁸. SARS-CoV-2 stock titer was 2.10⁷ PFU.mL⁻¹. Supernatant was aliquoted for storage at -80°C. 461

For viral titration, SARS-CoV-2 was titrated by lysis plaque assay as previously described ⁴⁹.
Vero E6 cells were plated onto 12-well plate at a density of 5.10⁴ cells per well in DMEM with
10% FBS. 24h later, cells were infected by 10 to 10 serial viral dilutions. After virus adsorption

for 1h at 37°C with plate rocking every 15 min, the viral inoculum was removed and Vero cells
were washed with PBS free medium. After, 500µL of an agarose medium mix was added. After
three days of incubation at 37°C with 5% CO2, supernatant was removed and cells were fixed
with 1 mL of 6% formalin solution for 30 minutes. The formalin solution was removed and cells
were colored with a 10% crystal violet solution for 15 minutes. All wells were then washed
with distilled water and dried on bench-coat paper before analysis.

471 For macrophages in vitro infection by SARS-CoV-2, CD14⁺ monocytes cells were isolated using StraightFrom[®] Whole Blood CD14 MicroBeads (#130-090-879, Miltenyi Biotec). 2.10⁵ 472 monocytes from one donor were added per culture well (96-flat-well plate). Monocytes were 473 differentiated into macrophages by incubating CD14⁺ monocytes cells for 7 days in X-VIVO15 474 (#BE02-060F, Lonza, Switzerland) with 50 ng.mL⁻¹ of GM-CSF (#130-093-864, Miltenyi Biotec). 475 For infection, macrophages were washed two times in PBS and were treated with virus in non-476 477 supplemented RPMI at a MOI of 0.3 and 3 as determined based on the viral titer and the number of cells plated, for 90 to 120 min at 37 °C. The macrophages were washed three times 478

with PBS before adding the lysis buffer into each well. The intracellular viral load Viral quantity

480 was then determined by RT-qPCR (see below).

481

479

482 **PBMC** preparation and coculture with macrophages:

PBMC were isolated from fresh blood samples using Lymphocyte Separation Media lymphosep LM-T1702/500 (Biosera). B cells, monocytes, and CD4⁺ cells were depleted from PBMC of the same healthy donors using Dynabeads[™] Untouched[™] CD8⁺ kit (#11348D, Invitrogen, USA) with an in-house antibody mix with the following biotinylated monoclonal anti-human antibodies CD4 (OKT4), CD14 (63D3) and CD19 (HIB19) from Biolegend. 2.10⁵

488	PBMCs or enriched MAIT cells per well were co-cultured with differentiated macrophages
489	during either 24h or 96 hours. Blocking antibodies were used against IL-12p70 (MAB219, R&D
490	systems) at 5µg.mL ⁻¹ and IL-18 (D044-3, MBL) at 5µg.mL ⁻¹ . 1 µg.mL ⁻¹ B18R (34-8185-81,
491	eBioscience) was used to block Type I interferons ⁵⁰ . After the coculture, macrophages were
492	washed three times with PBS before adding the lysis buffer into each well. The intracellular
493	viral quantity was then determined by RT-qPCR (see below).

494

495 **RNA extraction and RT-qPCR:**

496 Total nucleic acids from cells and supernatant were extracted with the Total NA Isolation kit -

497 Large Volume assay on a MagNA Pure LC 2.0 analyzer (Roche). Nucleic acids were eluted in

498 50μL of elution buffer and immediately tested by a quantitative PCR of the albumin gene for

499 cellular DNA⁵¹ and the RealStar[™] SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics GmbH) for

500 SARS-CoV-2 detection. Viral RNA quantification was achieved using a standardized RNA

501 transcript control acquired from the European Virus Archive Program.

502

503 Cytokine RNA quantification.

504 cDNA was produced from total extracted nucleic acids as described above using Superscript 505 III reverse transcriptase (#18080044; Invitrogen). Primers sequences used are described in 506 **Supplementary Table 2**. Quantitative PCR analysis was performed with SYBR Green (# 507 4887352001; Roche) and was analyzed with a LightCycler 480 (Roche). Relative expression 508 was calculated by the $2^{-\Delta\Delta Ct}$ method and was normalized to expression of the housekeeping 509 gene encoding 18S and, when detailed, normalized on mock-infected macrophages.

510

511 Statistics and Bioinformatics analysis:

All bioinformatics analyses were performed using RStudio (1.2.5) running on R software 512 version 4.0. We used the flowcytometry analysis R workflow from Nowicka et. al⁵² to produce 513 MDS (multidimensional scaling) plots of aggregated signal and normalized dimension 514 reduction plot UMAP and t-SNE with 500 MAIT cells per patient from Bichat hospital flow 515 516 cytometry data. Our pipeline combined this workflow with the flowWorkspace R library for 517 FlowJo workspace reading and cell population selection. Multiparametric matrix correlation plots were produced with the adjusted rcorr function from Hmisc and RcmdrMisc packages to 518 compute matrices of Spearman correlations along with the pairwise p-values corrected for 519 520 multiple inferences using Holm's method and visualized with the Corrplot package. Correlation plots hierarchical clustering were produced with the hclust function included in 521 522 the Corrplot library. Observations were filtered for missing values, and only complete 523 observations were used. Principal component analysis (PCA) was processed with FactoMineR library and graphically produced with Factoextra package. Heatmaps were plotted using 524 pheatmap library, with data centered to zero and scaled for each parameter. Clinical table 525 values were computed with the atable R library. All R code written and used from our study is 526 available at github.com/MatthieuRouland/MAIT-COVID19. 527

528 Statistical analyses were performed with GraphPad Prism software version 8.0 and R software 529 version 4.0. All datasets were tested for normal distribution using Shapiro-Wilk normality test. 530 Since all normality tests returned negative, all datasets were compared using nonparametric 531 two-tailed Mann-Whitney. Correlation calculation between two parameters has been 532 performed using the Spearman's correlation test corrected for multiple inferences using

- 533 Holm's method. Logistic regression and ROC (Receiver Operating Curve) were produced with
- 534 XLSTATS 2020.4 and confirmed with a randomly-split cohort on R with the RORC package.
- 535 Prognostic validity of the model was evaluated by analysis of the ROC curve and was measured
- using the area under the curve (AUC). Differences were considered significant at P < 0.05
- 537 (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).

539 Acknowledgments:

We thank all the patients and their physicians, nurses and technician staff who helped with 540 the study. We thank the Department of Biological Hematology and the Department of 541 542 Biochemistry of Bichat-Claude Bernard University Hospital for measuring white blood cells and C-reactive protein. We are grateful to Marc Diedisheim for biostatistics and bioinformatics 543 discussion, Quentin Le Hingrat for help in virus experiments, Antoine Costa Monteiro for help 544 545 in setting up the collaboration between virologists and immunologists, and the National Institutes of Health tetramer core facility for human MR1 tetramers. A.L. and R.C.M. 546 laboratories are supported by ANR-11-IDEX-0005-02 Laboratory of Excellence INFLAMEX and 547 Fondation pour la Recherche Médicale (EQU201903007779 to A.L. and EQU201903007816 to 548 R.C.M.). R. C. M. received a Université de Paris COVID-19 grant. A. L. is also supported by ANR-549 550 17-CE14-0002-01, ANR-19-CE14-0020, Fondation Francophone pour la Recherche sur le Diabète. A. L., C. B., A. V.-P. and JF. G. are supported by RHU QUID-NASH (ANR-17-RHUS-009); 551 M. R. and L.Ber. were supported by French Ministry of Research grants, A.T. and Z.G. were 552 553 supported by RHU QUID-NASH; C. R. was supported by Fondation Francophone contre le Diabète, P. S. was supported by Juvenile Diabetes Research Foundation. Servier Medical Art 554 555 for the free medical images (licensed under a Creative Commons Attribution 3.0 Unported License). 556

557

558 **Authors contribution:** H. F. collected most of the samples, clinical data and performed 559 experiments; M. R. performed experiments and all bioinformatics analyses. L. Bea. performed 560 experiments, analyzed data and managed experimental procedures. L. Ber analyzed data. A. 561 T. and S. Le. performed in vitro experiments. S. Lu. collected samples. Z. G., C. R. and P. S.

562	performed flow cytometry experiments and analyses. M.H.N. performed CBA and K. B. and M.
563	A. performed MSD Quickplex experiments. C. B., A. VP., JF. G., B. T., F. P., J. G., Y. Y. and JF.
564	T. performed patient recruitment and analyzed clinical parameters. B.V. and D.D isolated and
565	characterized SARS-CoV2. M. R., L. Bea., L. Ber., A. T., S. Le., H.F., R.C.M. and A. L. wrote the
566	manuscript. H.F., L. Bea, R. C. M. and A. L. conceived the study. A. L. supervised the study. All
567	authors edited and approved the manuscript.
568	
569	Conflict of interest statement: The authors declare no conflict of interest.
570	
571	Data availability statement: Data generated during this study will be available before
572	publication in a repository. Access code will be given upon request.
573	
574	Code availability statement: Code used during this study will be available before publication
575	in a repository. Access code will be given upon request.
576	

578 **References:**

- 1. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion
- 580 conformation. *Science* **367**, 1260–1263 (2020).
- 581 2. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19:
- immunity, inflammation and intervention. *Nature Reviews Immunology* 1–12 (2020)
- 583 doi:10.1038/s41577-020-0311-8.
- 584 3. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel
- 585 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513
- 586 (2020).
- 4. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in
 Wuhan, China. *Lancet* 395, 497–506 (2020).
- 5. Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute Respiratory Distress Syndrome. *N*.

590 Engl. J. Med. **377**, 562–572 (2017).

- 591 6. Matthay, M. A. et al. Acute respiratory distress syndrome. Nature Reviews Disease
- 592 *Primers* **5**, 1–22 (2019).
- 593 7. Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related
- 594 coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* 5,
- 595 536–544 (2020).
- Section 8. Crosby, C. M. & Kronenberg, M. Tissue-specific functions of invariant natural killer T cells.
 Nat Rev Immunol 18, 559–574 (2018).
- 598 9. McCarthy, N. E. & Eberl, M. Human γδ T-Cell Control of Mucosal Immunity and
- 599 Inflammation. *Front. Immunol.* **9**, (2018).
- 10. Toubal, A., Nel, I., Lotersztajn, S. & Lehuen, A. Mucosal-associated invariant T cells and
- 601 disease. *Nat. Rev. Immunol.* **19**, 643–657 (2019).

- 11. Trottein, F. & Paget, C. Natural Killer T Cells and Mucosal-Associated Invariant T Cells in
- Lung Infections. *Front Immunol* **9**, (2018).
- 12. Constantinides, M. G. et al. MAIT cells are imprinted by the microbiota in early life and
- 605 promote tissue repair. *Science* **366**, (2019).
- 13. Leng, T. et al. TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific
- Tissue Repair and Effector Functions. *Cell Rep* **28**, 3077-3091.e5 (2019).
- 14. Stehle, C., Hernández, D. C. & Romagnani, C. Innate lymphoid cells in lung infection and
- 609 immunity. *Immunol. Rev.* **286**, 102–119 (2018).
- 610 15. Vivier, E. *et al.* Innate Lymphoid Cells: 10 Years On. *Cell* **174**, 1054–1066 (2018).
- 16. Treiner, E. et al. Selection of evolutionarily conserved mucosal-associated invariant T
- 612 cells by MR1. *Nature* **422**, 164–169 (2003).
- 17. Corbett, A. J. *et al.* T-cell activation by transitory neo-antigens derived from distinct
- 614 microbial pathways. *Nature* **509**, 361–365 (2014).
- 18. Loh, L. et al. Human mucosal-associated invariant T cells contribute to antiviral influenza
- 616 immunity via IL-18-dependent activation. *Proc. Natl. Acad. Sci. U.S.A.* 113, 10133–10138
 617 (2016).
- 19. Ussher, J. E., Willberg, C. B. & Klenerman, P. MAIT cells and viruses. *Immunology & Cell Biology* 96, 630–641 (2018).
- 620 20. van Wilgenburg, B. *et al.* MAIT cells are activated during human viral infections. *Nat*
- 621 *Commun* **7**, 11653 (2016).
- 622 21. Ussher, J. E. *et al.* CD161++CD8+ T cells, including the MAIT cell subset, are specifically
- activated by IL-12+IL-18 in a TCR-independent manner. *Eur J Immunol* 44, 195–203
- 624 (2014).

- 625 22. Barathan, M. et al. Peripheral loss of CD8(+) CD161(++) TCRVα7·2(+) mucosal-associated
- invariant T cells in chronic hepatitis C virus-infected patients. *Eur. J. Clin. Invest.* 46, 170–
 180 (2016).
- 628 23. Leeansyah, E. *et al.* Activation, exhaustion, and persistent decline of the antimicrobial
- 629 MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood* **121**, 1124–1135
- 630 (2013).
- 24. Leeansyah, E. *et al.* Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7
 and Defective in HIV-1 Infection. *PLoS Pathog.* **11**, e1005072 (2015).
- 633 25. Wang, F. *et al.* Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19
- 634 Pneumonia. J. Infect. Dis. **221**, 1762–1769 (2020).
- 635 26. Silvin, A. *et al.* Elevated calprotectin and abnormal myeloid cell subsets discriminate
- 636 severe from mild COVID-19. *Cell* (2020) doi:10.1016/j.cell.2020.08.002.
- 637 27. Schulte-Schrepping, J. *et al.* Severe COVID-19 is marked by a dysregulated myeloid cell
- 638 compartment. *Cell* (2020) doi:10.1016/j.cell.2020.08.001.
- 639 28. Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe

640 COVID-19 patients. *Science* (2020) doi:10.1126/science.abc6027.

641 29. Zhang, J.-Y. et al. Single-cell landscape of immunological responses in patients with

642 COVID-19. *Nat. Immunol.* (2020) doi:10.1038/s41590-020-0762-x.

643 30. Jouan, Y. *et al.* Functional alteration of innate T cells in critically ill Covid-19 patients.

- 644 *medRxiv* 2020.05.03.20089300 (2020) doi:10.1101/2020.05.03.20089300.
- 645 31. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium-immune cell
- 646 interactions identified by single-cell analysis. *Nat. Biotechnol.* **38**, 970–979 (2020).
- 647 32. Dusseaux, M. et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi
- 648 IL-17-secreting T cells. *Blood* **117**, 1250–1259 (2011).

- 649 33. Hegde, P. et al. Mucosal-associated invariant T cells are a profibrogenic immune cell
- 650 population in the liver. *Nat Commun* **9**, 2146 (2018).
- 651 34. Rouxel, O. et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in
- 652 type 1 diabetes. *Nat. Immunol.* **18**, 1321–1331 (2017).
- 653 35. Magalhaes, I. et al. Mucosal-associated invariant T cell alterations in obese and type 2
- diabetic patients. J. Clin. Invest. **125**, 1752–1762 (2015).
- 655 36. Toubal, A. et al. Mucosal-associated invariant T cells promote inflammation and
- 656 intestinal dysbiosis leading to metabolic dysfunction during obesity. *Nat Commun* **11**,
- 657 3755 (2020).
- 658 37. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with
- 659 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062 (2020).
- 660 38. Cariou, B. et al. Phenotypic characteristics and prognosis of inpatients with COVID-19

and diabetes: the CORONADO study. *Diabetologia* **63**, 1500–1515 (2020).

- 662 39. Lisco, G. et al. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes
- 663 patients with COVID-19: a review. *Endocrine* (2020) doi:10.1007/s12020-020-02444-9.
- 40. Czernichow, S. et al. Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in
- 665 Paris hospitals, France: a cohort study on 5795 patients. *Obesity (Silver Spring)* (2020)

666 doi:10.1002/oby.23014.

- 41. Grimaldi, D. *et al.* Specific MAIT cell behaviour among innate-like T lymphocytes in
- 668 critically ill patients with severe infections. *Intensive Care Med* **40**, 192–201 (2014).
- 42. Cosgrove, C. et al. Early and nonreversible decrease of CD161++ /MAIT cells in HIV

670 infection. *Blood* **121**, 951–961 (2013).

- 43. Ishimori, A. et al. Circulating activated innate lymphoid cells and mucosal-associated
- 672 invariant T cells are associated with airflow limitation in patients with asthma.
- 673 *Allergology International* **66**, 302–309 (2017).
- 44. Lei, X. et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat
- 675 *Commun* **11**, 3810 (2020).
- 45. Dias, J., Leeansyah, E. & Sandberg, J. K. Multiple layers of heterogeneity and subset
- diversity in human MAIT cell responses to distinct microorganisms and to innate
- 678 cytokines. *Proc Natl Acad Sci U S A* **114**, E5434–E5443 (2017).
- 46. Leng, T. et al. TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific
- Tissue Repair and Effector Functions. *Cell Reports* **28**, 3077-3091.e5 (2019).
- 47. Blackley, S. et al. Primary human splenic macrophages, but not T or B cells, are the
- principal target cells for dengue virus infection in vitro. J. Virol. **81**, 13325–13334 (2007).
- 48. Hasnain, S. E. et al. Host-pathogen interactions during apoptosis. J. Biosci. 28, 349–358
- 684 (2003).
- 49. Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug
- 686 repurposing. *Nature* **583**, 459–468 (2020).
- 50. Symons, J. A., Alcamí, A. & Smith, G. L. Vaccinia virus encodes a soluble type I interferon
- receptor of novel structure and broad species specificity. *Cell* **81**, 551–560 (1995).
- 51. Désiré, N. et al. Quantification of human immunodeficiency virus type 1 proviral load by
- a TaqMan real-time PCR assay. J. Clin. Microbiol. **39**, 1303–1310 (2001).
- 52. Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-
- dimensional cytometry datasets. *F1000Res* **6**, 748 (2017).
- 693
- 694

Figure legends: 695

Figure 1. Immune cell frequencies and status in the blood of COVID-19 patients. (a) Graphical 696 697 representation of the COVID-19 cohort including a total of 182 patients from different hospitals and described as following: age, BMI, sex (F= Female, M= Male), diabetes, and 698 fatality rates. Mean (± SD) values for each medical ward are represented. (b-c) Whole blood 699 or Peripheral Blood Mononuclear Cells (PBMC) were collected from patients and analyzed 700 through flow cytometry. Flow cytometry analysis of CD3⁺ cells (b), $\alpha\beta T$ cells and $\gamma\delta T$ cells 701 702 frequencies (c) from uninfected controls (n=80), COVID-19 patients hospitalized in an Infectious Disease Unit (IDU) (n=62) or hospitalized in an Intensive Care Unit (ICU) (n=66). (d) 703 Flow cytometry analysis of CD4⁺ cells, regulatory T cells (Treg), and CD8⁺ T cell frequencies in 704 705 the blood of patients as described in (**b-c**). (e-f) Representative dot plots of V α 7.2 and CD161 706 staining to identify MAIT cells in blood of uninfected control and COVID-19 patients from IDU and ICU, and MAIT cell (e) and CD8⁺ MAIT cell (f) frequencies in the blood of patients as 707 described in (b-c). SSC, side scatter. Small horizontal lines indicate the median, each symbol 708 709 represents one biological sample. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (twosided Mann-Whitney nonparametric test). 710

711

712 Figure 2. Blood MAIT cells are activated and secrete pro-inflammatory cytokines in COVID-713 19 patients. (a) Representative dot plots of CD69, CD56, and double-positive surface markers expression on blood MAIT cells from one uninfected control and two COVID-19 patients 714 admitted in Infectious Disease Unit (IDU) and Intensive Care Unit (ICU) respectively. CD69⁺, 715 CD56⁺, and CD56⁺ CD69⁺ MAIT cells frequencies in the blood of uninfected (n=80), and infected 716 717 patients from IDU (n=62) and ICU (n=66). (b-c) Multi-Dimensional Scaling (MDS) plot (b) and

Uniform Manifold Approximation and Projection (UMAP) (c) analysis of MAIT cells for each 718 uninfected (n=23) and infected patient from IDU (n=50) or ICU (n=66) from Bichat hospital 719 analyzed with the same flow cytometer. (d) UMAP divided by groups and colored by the scaled 720 expression of CD69 and CD56. (e-f) Representative dot plots and frequencies of IFNy (e), 721 722 granzyme B (GzB) (f) in MAIT cells after stimulation from uninfected controls (n=25-27), 723 COVID-19 patients hospitalized in an Infectious Disease Unit (IDU) (n=14-15) or hospitalized in an Intensive Care Unit (ICU) (n=15). (g) Representative dot plots and frequencies of GzB⁺ MAIT 724 cells without stimulation in uninfected controls (n=19), IDU (n=11), and ICU (n=14) COVID-19 725 patients. SSC, side scatter. Small horizontal lines indicate the median, each symbol represents 726 one biological sample. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (two-sided Mann-727 728 Whitney nonparametric test).

729

Figure 3: MAIT cells phenotype correlates with ILC and vot cells alteration in COVID-19 730 731 patients. (a-b) Frequencies of NK, ILC2, and ILC3 innate immune cells among CD3⁻ CD19⁻ cells (a) and CD69 activation surface marker on NK, ILC2, ILC3, and yoT cells (b) in uninfected 732 controls (n=80), COVID-19 patients hospitalized in an Infectious Disease Unit (IDU) (n=62) or 733 hospitalized in an Intensive Care Unit (ICU) (n=66). (c) Multiparametric matrix correlation plot 734 of MAIT, $v\delta T$, ILCs, and NK cells frequencies, surface marker, and intracytoplasmic staining in 735 COVID-19 patients. Spearman's correlation coefficients are visualized by square size and color 736 intensity. Variables are ordered by hierarchical clustering. (d) Correlation between CD69⁺ 737 MAIT cells and CD69⁺ NK, CD69⁺ ILC3 or CD69⁺ γδT cells in COVID-19 patients (n=102). Small 738 horizontal lines indicate the median, each symbol represents one biological sample. *P<0.05, 739 740 **P<0.01, ***P<0.001, and ****P<0.0001 (two-sided Mann-Whitney nonparametric test and 741 Spearman nonparametric correlation test corrected for multiple inferences using Holm's 742 method).

743

Figure 4. MAIT cell activation and functions are altered in fatal compared to non-fatal COVID-744 19. (a) Frequency of CD69⁺ cells among MAIT cells, conventional CD8⁺ and CD4⁺ T cells, $\gamma\delta T$ 745 746 and NK cells in the blood of uninfected controls (n=80), surviving COVID-19 cases hospitalized 747 in an Infectious Disease Unit (IDU) (n=45) or hospitalized in an Intensive Care Unit (ICU) (n=30) 748 and fatal cases from both IDU and ICU (n=27). (b) Circular barplot representative negative 749 natural logarithm p-values of the frequency of immune cells (MAIT, CD8⁺, CD4⁺, CD3⁻, $\gamma\delta$ T) function including IL-2⁺, IL-4⁺, IL-10⁺, IL-17⁺, IFNy⁺, TNF⁺, and GzB⁺ after stimulation or GzB⁺ 750 751 without stimulation (Unstim) between fatal (n=5-6) and non-fatal (n=16-23) SARS-CoV-2 infected patients. The red-dotted circle represents a p-value of 0.05. (c) Receiver-operating-752 753 characteristic (ROC) curves of the predictive MAIT cell markers defining the outcome of 754 COVID-19. (d) Heatmap showing the scaled expression of different innate-like immune cells activation (MAIT, ILC3, NK, γδT, CD8), C-reactive protein (CRP), and polynuclear neutrophil 755 (PPN) ordered by hierarchical clustering in uninfected controls (n=13), IDU (n=13), non-fatal 756 757 ICU (n=9) and fatal ICU (n=6). Each symbol (a) or columns (d) represents one patient. Upregulated parameters are shown in red, and down-regulated parameters are shown in navy 758 blue. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (two-sided Mann-Whitney 759 760 nonparametric test).

761

Figure 5. Pro-inflammatory cytokines are elevated in COVID-19 patients and match with
 MAIT cell activation and cytokine secretion. (a) Cytometric Bead Array (CBA) cytokine

764 quantification of IL-6, IL-8, and IL-10 in the blood of surviving COVID-19 cases hospitalized in Infectious Disease Unit (IDU) (n=19-22) or hospitalized in Intensive Care Unit (ICU) (n=19-28) 765 and fatal cases (n=25). (b) MSD Quickplex cytokine guantification of IFN α 2, IL-1 β , IL-15, and 766 IL-18, in the blood of surviving COVID-19 cases hospitalized in IDU (n=14-22) or hospitalized in 767 768 ICU (n=16-28) and fatal cases (n=20-25). Values under the limit of detection are not statistically 769 computed and are not displayed. (c) Multiparametric matrix correlation plot of IL-6, IL-8, IL-15, IL-18, IFNα cytokines blood level; frequencies of CD69⁺, CD56⁺, CD69⁺ CD56⁺, and GzB⁺ 770 MAIT cells; frequencies of IFN γ^+ , IL-2⁺, TNF⁺, and GzB⁺ stimulated MAIT cells; in non-fatal 771 772 (upper right part, n=30) versus fatal COVID-19 patients in ICU (lower left part, n=21). 773 Spearman's correlation coefficients are visualized by square size and color intensity. Variables 774 are ordered by alphabetical order. (d) CD69⁺ MAIT cells, IL-18, and IFN α blood levels according to symptoms duration (days) in COVID-19 patients, starting at the first clinical sign. Small 775 776 horizontal lines indicate the median, each symbol represents one patient. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001 (two-sided Mann-Whitney nonparametric test and Spearman 777 nonparametric correlation test corrected for multiple inferences using Holm's method). 778

779

Figure 6: MAIT cell phenotype and blood cytokine levels are associated with SARS-CoV-2 infection severity. (a-c) Pulmonary damages score level (1: light - 5: critical) (a), PaO₂/FiO₂ ratio (b) and C-Reactive protein (CRP) (c) of surviving COVID-19 cases hospitalized in Infectious Disease Unit (IDU) (n=38, n=17, n=44) or hospitalized in Intensive Care Unit (ICU) (n=15, n=30, n=27) and fatal cases from IDU and ICU (n=20, n=27, n=23). (d) Multiparametric matrix correlation plot of the following clinical data: age, BMI, CRP, SAPS II score, PaO₂/FiO₂, Polymorphonuclear neutrophils (PMN), Disease duration, Pulmonary lesions score);

787 frequencies of CD69⁺, CD56⁺, CD69⁺ CD56⁺, CCR6⁺ CD127⁺, and GzB⁺ MAIT cells; frequencies of IFNy⁺, IL-2⁺, TNF⁺, and GzB⁺ stimulated MAIT cells; in the blood of all COVID-19 patients. 788 Spearman's correlation coefficients are visualized by square size and color intensity. Variables 789 are sorted by hierarchical clustering. (e) Correlation between PaO₂/FiO₂ ratio (n=73), SAPS II 790 791 score (n=46), CRP (n=94), and PMN (n=101) and the frequency of CD69⁺ MAIT cells in blood 792 (presented as a % value of total MAIT cells) from all COVID-19 patients. (f-g) Principal component analysis (PCA) of 50 variables (listed in Supplementary Fig. 9) including clinical data 793 and frequencies of immune cell phenotype in IDU (n=46), ICU (n=30), and fatal cases from IDU 794 (n=6) and ICU (n=21) infected patients. Each point represents a single patient. Mean value of 795 796 each group is symbolized by a bigger symbol (f). Arrows represent quantitatively the 797 contributions of each variable in the PCA, the first 40 contributing parameters are displayed. Mean values of groups are represented by a symbol. Concentration ellipses with a confidence 798 799 of 95% are shown (g). Small horizontal lines indicate the median, each symbol represents one patient. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 (two-sided Mann-Whitney 800 801 nonparametric test and Spearman nonparametric correlation test corrected for multiple inferences using Holm's method). 802


803


804 Figure 7: Infected macrophages are altered and trigger MAIT cells *in vitro*.


PBMCs of uninfected patients are challenged with infected macrophages with the SARS-CoV-2 virus. (**a**) Graphical flowchart of the *in-vitro* co-culture experiments. (**b**) Representative dot plot and frequency of CD69⁺ MAIT cells in 4 healthy donors co-cultured with different SARS-CoV-2 Multiplicity of Infection (MOI) with mock, 0.3, and 3, with replicates (n=2-4). Each symbol represents the mean value of replicates. (**c**) Viral quantification of SARS-CoV-2 in co-


810	culture from four donors at 96h, by RT-qPCR. (d-e) Frequency of CD69 ⁺ cells among MAIT cells,
811	conventional CD8 ⁺ and CD4 ⁺ T cells, $\gamma\delta T$ and NK cells in donor n°4 (d) and all donors (e) co-
812	culture at 96h, with replicates (n=2-4). (f) Kinetic of $Ifn\alpha$, $Ifn\beta$, $II-1\beta$, $II-6$, $II-7$, $II-10$, $II-15$, and $II-10$
813	18 mRNA relative levels in infected macrophages from two healthy donors at 24h, 48h, and
814	96h after infection. (g) Co-culture of infected macrophages (MOI 3) with PBMC (donor 4) or
815	purified T cells (donor 5) with or without anti-IL-12, anti-IL-18, or recombinant soluble IFN α
816	receptor protein (B18R), with replicates (n=2-4). Each symbol represents a single co-culture
817	well.

All rights reserved. Group	Uninfected control	is in the second	ICU
Number of patients	80	51	51
Sex			
Female	40% (32)	33%~(17)	18% (9)
Male	60% (48)	67% (34)	82% (42)
Age			
Median (MAD)	58 ± 20.9	61 ± 14.8	59 ± 14.8
Mean (SD)	54.9 ± 17.5	61 ± 16.4	57.6 ± 13.3
Range	23-78.8	23-98	29-83
BMI			
Median (MAD)	28 ± 4.6	30 ± 5.3	29 ± 5.9
Mean (SD)	27.2 ± 4.9	28.9 ± 5.3	29.8 ± 5.4
Range	18-38.3	17-38	21-43
Hospital			
Bichat	32% (26)	86% (44)	94% (48)
Cochin	26% (21)	14% (7)	5.9% (3)
Beaujon-Lariboisière	26% (21)	0% (0)	0% (0)
EFS	15% (12)	0%~(0)	0% (0)
Disease duration (days)			
Median (MAD)	-	10 ± 5.9	18.5 ± 13.3
Mean (SD)	-	13.5 ± 11.9	24.5 ± 16.7
Range	-	0-67	4-65
Deaths	0% (0)	12%~(6)	41% (21)
Treaments			
Tocilizumab	0% (0)	2% (1)	12% (6)
Anakinra	0% (0)	12% (6)	33% (17)
Lopinavir/Ritonavir	0% (0)	33% (17)	57% (29)
Anti-IFNβ	0% (0)	2% (1)	3.9%(2)
Dexamethasone	0% (0)	20% (10)	67% (34)
Hydroxychloroquine	0% (0)	5.9%~(3)	18% (9)
Pulmonary lesions			2.007 (2)
Mild (score = 1)	0% (0)	12% (6)	3.9% (2)
Moderate (score = 2)	0% (0)	33% (17)	5.9% (3)
Severe (score $= 3$)	0% (0)	27% (14)	24% (12)
Grievous (score $= 4$) Critical (score $= 5$)	$0\% (0) \\ 0\% (0)$	$12\% (6) \\ 0\% (0)$	$20\% (10) \\ 3.9\% (2)$
Missing	100% (80)	16% (0)	43% (22)
	10070 (00)	1070 (0)	4070 (22)
Pulmonary lesions score		2 ± 1.5	9 1 5
Median (MAD)	-		3 ± 1.5
Mean (SD) Range	-	$2.5 \pm 0.9 \\ 1-4$	3.2 ± 1 1-5
	-	1-4	1-0
PaO2/FiO2		200 5 1 100 1	150 1100 0
Median (MAD)	-	306.5 ± 160.1	158 ± 108.2
Mean (SD) Range	-	345.3 ± 176.9 88-700	194.2 ± 144.8 55-948
	-	88-700	00-940
SAPS II score			05 110.0
Median (MAD)	-	22 ± 0	35 ± 16.3
Mean (SD)	-	28.4 ± 17.9	37.3 ± 15.9
Range	-	16-60	9-78
Polymorphonuclear neutrophils (PMN)			0 - 1
Median (MAD)	4.2 ± 1.9	3.7 ± 2.2	9.7 ± 4.8
Mean (SD)	4.3 ± 1.8	4.4 ± 2.7	10.6 ± 6
Range	2.1-8.5	1.1 - 15.7	2.9-30.2
C-Reactive protein (CRP)			
Median (MAD)	1.5 ± 1.2	66 ± 60.8	95.2 ± 93.4
Mean (SD)	2.6 ± 2.1	72.2 ± 59.3	125.7 ± 97.6
Range	0.2-6.9	3-241	6-428
Procalcitonin (PCT)			
Median (MAD)	-	0.1 ± 0.1	0.3 ± 0.3
Mean (SD)	-	3.3 ± 12.9	1.5 ± 4.1
Range	-	0-55	0-18
Type 2 Diabetes	38% (30)	27% (14)	18% (9)
HbA1c			
Median (MAD)	7.4 ± 0.9	7.7 ± 1.9	6.6 ± 0.7
Mean (SD)	7.6 ± 1	8.1 ± 2.4	6.8 ± 1.2
Range	5.3 - 10.2	5.1 - 16.1	5.1 - 10.4
		F 007 (8)	F107 (0C)
Secondary Infection	0% (0)	5.9% (3)	$\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$
Secondary Infection Hospital acquired pneumonia	$0\% (0) \\ 0\% (0)$	$5.9\% (3) \ 4\% (2)$	51% (26) 29.4% (15)












Figure 3





Figure 4



Days after symptoms onset

Days after symptoms onset

Figure 5

Days after symptoms onset




Figure 6

FUI 12.4%




Figure 7